Inclusion Criteria:  Provision of signed and dated informed consent form Adults (18 years or older) Cognitively impaired adults are not excluded (i.e. will be included in the study) Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs) EEG consistent with focal or generalized epilepsy Patients must have >4 focal aware, focal impaired aware, focal to bilateral tonic clonic or generalized tonic clonic seizures per month. Patients can be on >/= 1 anti-seizure medication (ASM) at the time of enrollment on stable doses 12 weeks prior to initiation Patients on Epilepsy devices: Vagal nerve stimulator (VNS), Deep brain stimulator (DBS) or Responsive Nerve Stimulator (RNS) must have remained stable for at least 4 weeks before the screening visit. Adjustment of devices is not allowed during the study.  Exclusion Criteria  Patients <18 years of age Pregnant women Women that are breast feeding Patients who had >21 days of seizure freedom in the last year. Patients with a history of status epilepticus within 3 months of screening Patients with a history of alcoholism of drug misuse within the last 2 years Unstable medical illness Serious or imminent suicidal or homicidal risk Patients with cardiovascular disease Patients with schizophrenia Patients with history of aneurysm or aortic dissection, arteriovenous malformation and intracerebral hemorrhage Patients that are immobile i.e. wheel chair bound, bed ridden individuals Patients on psychostimulants (amphetamines, methylphenidate etc.) and Monoamine oxidase inhibitors (selegiline, isocarboxazid, phenelzine etc.)